focus -WSS

focus

author：knowledge 2025-09-10 05:00:35 - browse：7

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Vertex non

focus

WSS

Quicker fix for pulse oximeters urged during FDA public meeting

In medicine, common shorthands can shortchange care

Novo Nordisk to expand supply of Wegovy for U.S. patients

General Catalyst, Summa Health deal will turn on physician buy

Appeals court upholds Josh Duggar's conviction for downloading child sex abuse images

Apple Vision Pro: A first look at health apps on the new VR headset

knowledge

focus

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

Illinois to ban advertising for guns allegedly marketed to kids and militants

Activists slam private health insurers over coverage restrictions

Novo Nordisk to expand supply of Wegovy for U.S. patients

Trump demands the U.S. pay no more for drugs than other countries … again

Commercial surrogacy can be ethical, despite pope’s claims

How to save PrEP access — and even expand it

Time to name cancers by genetics, not organ of origin, expert says

DIEP, the 'gold standard' of breast reconstruction, is under threat

Juul spent big to court Black leaders to promote its e

focus

Trump lawyer welcomes Pence testifying in Jan. 6 trial, won't say if Trump will too

Time to name cancers by genetics, not organ of origin, expert says

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

The real point of Kenneth Smith’s execution by nitrogen gas

A $475,000 price tag for a new cancer drug: crazy or meh?

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

explore

knowledge

focus

hotspot